Enavatuzumab
Enavatuzumab (pronounced as en-av-a-tuz-u-mab) is a type of monoclonal antibody that is being studied in the treatment of certain types of cancer. It binds to a protein called TWEAK receptor, which is found on the surface of some types of cancer cells. This may help the immune system kill cancer cells. It is a type of immunotherapy.
Etymology
The name "Enavatuzumab" is derived from the International Nonproprietary Names (INNs), in which 'zu' denotes humanized antibody, 'mab' is indicative of monoclonal antibody, and 'Enavatu' is a unique stem.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. There are many kinds of monoclonal antibodies. A monoclonal antibody is made so that it binds to only one substance.
- TWEAK receptor: A protein found on the surface of some cells that binds to another protein called TWEAK. It may be found in higher than normal amounts on cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- Cancer: A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems.
See Also
External links
- Medical encyclopedia article on Enavatuzumab
- Wikipedia's article - Enavatuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski